share_log

DEF 14A: Definitive information statements

DEF 14A: Definitive information statements

DEF 14A：股東委託書決議
美股SEC公告 ·  09/18 17:03

Moomoo AI 已提取核心訊息

Heart Test Laboratories, Inc. (HeartSciences) has filed its definitive proxy statement with the U.S. Securities and Exchange Commission (SEC) on September 18, 2024, for its upcoming Annual Meeting of Shareholders scheduled for November 7, 2024. The meeting will be held virtually via a live audio webcast. Shareholders will vote on the ratification of Haskell & White LLP as the company's independent registered public accounting firm for the fiscal year ending April 30, 2025, and on the approval of an adjournment of the Annual Meeting if necessary to solicit additional proxies. The company did not hold a 2023 Annual Meeting of Shareholders, and as such, is soliciting approval for both its Class I and Class II director nominees collectively. The sole Class III director nominee's term expires at the 2025 Annual Meeting, and therefore, no approval for this position is sought at the current meeting. Shareholders as of the record date, September 16, 2024, are entitled to vote, and the company has provided various methods for shareholders to submit their proxies.
Heart Test Laboratories, Inc. (HeartSciences) has filed its definitive proxy statement with the U.S. Securities and Exchange Commission (SEC) on September 18, 2024, for its upcoming Annual Meeting of Shareholders scheduled for November 7, 2024. The meeting will be held virtually via a live audio webcast. Shareholders will vote on the ratification of Haskell & White LLP as the company's independent registered public accounting firm for the fiscal year ending April 30, 2025, and on the approval of an adjournment of the Annual Meeting if necessary to solicit additional proxies. The company did not hold a 2023 Annual Meeting of Shareholders, and as such, is soliciting approval for both its Class I and Class II director nominees collectively. The sole Class III director nominee's term expires at the 2025 Annual Meeting, and therefore, no approval for this position is sought at the current meeting. Shareholders as of the record date, September 16, 2024, are entitled to vote, and the company has provided various methods for shareholders to submit their proxies.
Heart Test Laboratories, Inc.（HeartSciences）於2024年9月18日向美國證券交易委員會（SEC）提交了其明確的代理聲明，並計劃於2024年11月7日舉行的年度股東大會上審議。該會議將通過實況音頻網絡廣播的方式進行虛擬舉行。股東將就覈准Haskell & White LLP擔任公司獨立註冊的公共會計師事務所的投票，以及必要時就年度大會的延期進行額外的代理徵集。公司未舉行2023年股東年會，因此正在共同尋求對其I類和II類董事候選人的批准。唯一的III類董事候選人的任期將於2025年股東年會屆滿，因此不會在當前會議上尋求對該職位的批准。截至2024年9月16日，持股人有權投票，並且該公司已提供了多種方式供持股人提交代理投票。
Heart Test Laboratories, Inc.（HeartSciences）於2024年9月18日向美國證券交易委員會（SEC）提交了其明確的代理聲明，並計劃於2024年11月7日舉行的年度股東大會上審議。該會議將通過實況音頻網絡廣播的方式進行虛擬舉行。股東將就覈准Haskell & White LLP擔任公司獨立註冊的公共會計師事務所的投票，以及必要時就年度大會的延期進行額外的代理徵集。公司未舉行2023年股東年會，因此正在共同尋求對其I類和II類董事候選人的批准。唯一的III類董事候選人的任期將於2025年股東年會屆滿，因此不會在當前會議上尋求對該職位的批准。截至2024年9月16日，持股人有權投票，並且該公司已提供了多種方式供持股人提交代理投票。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間